Vertex Pharmaceuticals and Orna Therapeutics have announced plans to partner on gene therapies for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).  The three-year strategic research collaboration will utilise Orna’s lipid nanoparticle (LNP) delivery solutions.  In return Orna will receive upfront payments of $65 million, including an investment in the form of a convertible […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!